Accelerated drug development through combined phase 2/3 clinical trial design

Archives of Ophthalmology

Volumn 122, Issue 7, 2004, Pages 1043-1044

  Cunningham Jr , Emmett T ^a   Da Silva, Loni ^b   Harrison, Evelyn M ^b   Modi, Marlene W ^b   O'Shaughnessy, Denis ^b   Guyer, David R ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MEMANTINE; RECOMBINANT ALPHA2A INTERFERON; VASCULOTROPIN ANTIBODY; NEW DRUG;

CLINICAL RESEARCH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DESIGN; DRUG RESEARCH; DRUG SAFETY; GLAUCOMA; HUMAN; NEUROPROTECTION; OPHTHALMOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SIDE EFFECT; STATISTICAL ANALYSIS; VISUAL FIELD DEFECT; ARTICLE; DRUG SCREENING; METHODOLOGY;

CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG DESIGN; DRUG EVALUATION; DRUGS, INVESTIGATIONAL; HUMANS; RESEARCH DESIGN;

EID: 3342985034     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.122.7.1043     Document Type: Review

References (8)

1. Amberson JB Jr, McMahon BT, Pinner M. A clinical trial of sanocrysin in pulmonary tuberculosis. Am Rev Tuberc. 1931;24:401-435.
2. Zivin JA. Understanding clinical trials. Sci Am. 2000;282:69-75.
3. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. 3rd ed. New York, NY: Springer: 1998.
4. Kramar A, Ptovin D, Hill C. Multistage designs for phase II clinical trials: statistical issues in cancer research. Br J Cancer. 1996;74:1317-1320.
5. Liu PY, LeBlanc M, Desai M. False positive rates of randomized phase II designs. Control Clin Trials. 1999;20:343-352.
6. The Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 2002;22:143-152.
7. Heier JS, Greene WL, rhuFabV2 Study Group. RhuFabV2 (an Anti-VEGF antibody fragment) in neovascular AMD: safety and tolerability of multiple intravitreal injections. Invest Ophthalmol Vis Sci. 2002;43:2520a.
8. Pharmacological Therapy for Macular Degeneration Study Group. Interferon Alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol. 1997;115:865-872.